Pipeline

Pipeline

FIMECS has the following pipelines.

  • Target
  • Target class
  • Target Indication
  • Discovery
  • IND-enabling
  • Clinical Studies
  • Partner

Target:IRAK-M

Target class:pseudokinase

Target Indication:Non-small cell lung cancer Pancreatic cancer, etc.
Discovery IND-enabling Clinical Studies FIM-001

IRAK-M (interleukin 1 receptor associated kinase 3) belongs to the pseudokinase family and has been considered “undruggable”. It is known as a negative regulator of the MyD88-dependent TLR/IL1R pathway and is specifically expressed in myeloid cells to suppress excessive activation of innate immunity. IRAK-M degraders are expected to be attractive cancer immunotherapeutic agents with a mechanism of action that release immunosuppressive property in myeloid cells in cancer patients.

Read More

More Hide

Target:TRIB1

Target class:pseudokinase

Target Indication:Oncology
Discovery IND-enabling Clinical Studies

TRIB1 (Tribbles homolog 1) belongs to pseudokinase family and has been con“idered "undruggable”. It is a cooperative gene for Hoxa9, an important leukemia-causing gene, and its expression is enhanced in many acute myeloid leukemia subtypes. TRIB1 degraders are expected to show efficacy against Hoxa9-dependent acute myeloid leukemia.

More Hide

Target:Undisclosed

Target class:Undisclosed

Target Indication:Oncology
Discovery IND-enabling Clinical Studies パートナー

Undisclosed

More Hide

Target:Undisclosed

Target class:Undisclosed

Target Indication:Oncology
Discovery IND-enabling Clinical Studies パートナー

Undisclosed

More Hide